Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
Regeneron Is 'One Of The Stronger Growers In Biotech'
Regeneron CEO And CFO Met With Citi: Here Are The Takeaways
Lilly, J&J, Novo Battle Diabetes -- And Each Other (Investor's Business Daily)
Related AGN
Allergan Files De Novo Application For Approval Of Oculeve Intranasal Tear Neurostimulator
5 Stocks That Had A Lot Of Social Chatter This Week With Low Investor Confidence
What To Do With Your Relypsa Winnings (Seeking Alpha)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Jun 2016BernsteinInitiates Coverage onOutperform
Apr 2016Wells FargoDowngradesOutperformMarket Perform
Apr 2016Leerink SwannMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

View Comments and Join the Discussion!